Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates
Portfolio Pulse from
Xeris Biopharma (XERS) reported a Q4 loss of $0.03 per share, which was better than the expected loss of $0.07 per share. However, the company missed revenue estimates.
March 06, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Xeris Biopharma reported a Q4 loss of $0.03 per share, better than the expected $0.07 loss, but missed revenue estimates. This mixed result may lead to short-term volatility in the stock price.
The better-than-expected EPS loss suggests some positive operational performance, but missing revenue estimates could concern investors. This mixed outcome is likely to cause short-term volatility in XERS stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100